These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22580938)

  • 21. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
    Akahoshi K; Ban D; Kuboki R; Oba A; Ono H; Mitsunori Y; Kudo A; Tanaka S; Tanabe M
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1108-1115. PubMed ID: 30242888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
    Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
    Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A
    J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
    Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
    Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
    Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
    Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
    Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments.
    Tavolari S; Deserti M; Vasuri F; Curti S; Palloni A; Pinna AD; Cescon M; Frega G; De Lorenzo S; Barbera MA; Garajova I; Ricciardiello L; Malvi D; D'Errico-Grigioni A; Pantaleo MA; Brandi G
    Eur J Cancer; 2019 Jan; 106():160-170. PubMed ID: 30528800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma.
    Gürlevik E; Fleischmann-Mundt B; Armbrecht N; Longerich T; Woller N; Kloos A; Hoffmann D; Schambach A; Wirth TC; Manns MP; Zender L; Kubicka S; Kühnel F
    Hepatology; 2013 Sep; 58(3):1031-41. PubMed ID: 23686746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
    Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
    Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
    Vincenzi B; Stacchiotti S; Collini P; Pantano F; Rabitti C; Perrone G; Iuliani M; Baldi A; Badalamenti G; Sanfilippo R; Santini D; Muda AO; Gronchi A; Casali P; Dei Tos AP; Tonini G
    Br J Cancer; 2017 Jul; 117(3):340-346. PubMed ID: 28641307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
    Xiao JC; Zhang TP; Zhao YP
    Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
    Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
    PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
    Nordh S; Ansari D; Andersson R
    World J Gastroenterol; 2014 Jul; 20(26):8482-90. PubMed ID: 25024604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
    Shiozaki S; Satoh D; Matsukawa H; Yamaguchi K; Takahashi K; Mimura N; Taguchi K; Araki H; Toshima T; Kato T; Miyake S; Miyoshi H; Yoshida K; Choda Y; Tokumoto N; Kanazawa T; Harano M; Ojima Y; Idani H; Okajima M; Ninomiya M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2089-91. PubMed ID: 25731432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
    Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
    Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
    Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
    Br J Cancer; 2018 Apr; 118(7):947-954. PubMed ID: 29515256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
    Oguri T; Achiwa H; Muramatsu H; Ozasa H; Sato S; Shimizu S; Yamazaki H; Eimoto T; Ueda R
    Cancer Lett; 2007 Oct; 256(1):112-9. PubMed ID: 17658213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.